News stories about Nightstar Therapeutics PLC Sponsored ADR (NASDAQ:NITE) have trended somewhat positive this week, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Nightstar Therapeutics PLC Sponsored ADR earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media coverage about the company an impact score of 47.3071192399201 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Nightstar Therapeutics PLC Sponsored ADR (NITE) traded down $1.29 during midday trading on Friday, hitting $20.01. The company had a trading volume of 96,100 shares, compared to its average volume of 103,458. Nightstar Therapeutics PLC Sponsored ADR has a 12 month low of $14.56 and a 12 month high of $24.93.

NITE has been the topic of several recent analyst reports. BMO Capital Markets initiated coverage on Nightstar Therapeutics PLC Sponsored ADR in a research note on Monday, October 23rd. They issued an “outperform” rating and a $30.00 target price on the stock. Jefferies Group LLC initiated coverage on Nightstar Therapeutics PLC Sponsored ADR in a research note on Monday, October 23rd. They issued a “buy” rating and a $25.00 target price on the stock. Leerink Swann initiated coverage on Nightstar Therapeutics PLC Sponsored ADR in a research note on Monday, October 23rd. They issued an “outperform” rating and a $25.00 target price on the stock. Finally, Wedbush initiated coverage on Nightstar Therapeutics PLC Sponsored ADR in a research note on Monday, October 23rd. They issued an “outperform” rating and a $19.00 target price on the stock.

ILLEGAL ACTIVITY WARNING: This article was posted by Watch List News and is owned by of Watch List News. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://www.watchlistnews.com/nightstar-therapeutics-plc-sponsored-adr-nite-receiving-somewhat-favorable-news-coverage-analysis-finds/1696781.html.

About Nightstar Therapeutics PLC Sponsored ADR

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.

Receive News & Ratings for Nightstar Therapeutics PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics PLC Sponsored ADR and related companies with Analyst Ratings Network's FREE daily email newsletter.